NYSE:ZTSPharmaceuticals
Zoetis Resets Outlook As U.S. Pet Weakness Pressures Valuation And Growth
Zoetis (NYSE:ZTS) has cut its full year guidance after a sharp downturn in its U.S. companion animal business.
Management points to higher price sensitivity among pet owners, fewer veterinary visits, and more generic competition as key pressures.
The company is refocusing on integrated solutions, tighter cost controls, and operational efficiency as part of a broad reset.
For investors, the reset lands on top of a steep share price pullback. Zoetis now trades at $87.31, with the stock down...